Please select the option that best describes you:
How do you modify HMA treatments for a patient with high-risk MDS experiencing prolonged cytopenias after each cycle?
What ANC and platelet thresholds do you use?
Answer from: Medical Oncologist at Community Practice
When using azacitidine for the treatment of MDS, I adjust the dose in case of cytopenia for cycle 2 onwards.
If there was no baseline cytopenia (ANC >1.5, PLT >75K) but cytopenia developed with treatment, the subsequent cycle is delayed until counts recover, and the dose is based on the nad...
Sign In or Register to read more